Simple preclinical experiments should be able to predict whether immunotherapeutic medicines are safe to advance to preclinical testing in humans and avoid the Northwick Park trial that left six healthy volunteers hospitalised.
MedImmune has announced that interim Phase I results for its new
monoclonal antibody (MAb) suggest that it is well tolerated and
shows biological activity in adults with asthma.
A novel drug designed to prevent coronary heart disease has failed
a pivotal clinical trial although the developers are hopeful the
drug might still win approval.
In the light of the death of former Russian security agent,
Alexander Litvinenko, pharma companies developing anti-radiation
drugs are increasingly under the spotlight.
A unique DNA-based targeting technology has shown to halt tumour
progression with significantly smaller chemotherapy doses opening
the way to reduce the side effects as well as increase the efficacy
of anti cancer therapies.
Researchers at Harvard Medical School in the US have developed a
way to rapidly screen compounds for potential therapeutic activity
in diseases where current screening methods are limited.
